Literature DB >> 1953684

p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells.

P J Higgins1, M P Ryan.   

Abstract

Flat revertants of v-ras-transformed (KNRK) rat kidney cells, which express elevated levels of p21ras protein, were generated to high efficiencies with sodium butyrate (NaB). Overall protein synthesis in revertants was not different from parental cells, although changes were evident in expression and distribution of specific microfilament-associated cytoskeletal proteins. Quantitative two-dimensional electrophoresis revealed revertant-associated 3-4-fold increases in cytoskeletal deposition of the microfilament-associated proteins gelsolin and vinculin correlating with microfilament reorganization and focal-contact formation respectively. Similar increases in actin content were evident at both the total-cellular- and cytoskeletal-associated-protein levels. In contrast, intermediate-filament family elements (vimentin, lamins) remained unaltered. The only unique protein resolved in flat revertants was p52, a 52 kDa extracellular-matrix-associated protein previously identified as plasminogen-activator inhibitor type 1 (PAI-1). p52(PAI-1) expression was induced early during generation of the revertant phenotype and preceded development of focal-contact structures. NaB-induced p52(PAI-1) synthesis and generation of early morphological reversion in KNRK cells required ongoing RNA synthesis, since exposure to actinomycin D before addition of NaB inhibited both events. p52(PAI-1) induction by NaB was regulated at the level of mRNA abundance; in contrast, actin mRNA levels were the same in parental and revertant cells, suggesting that the increased actin content which typified the revertant phenotype was due to augmented actin microfilament stability.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1953684      PMCID: PMC1151528          DOI: 10.1042/bj2790883

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Interferon-induced revertants of ras-transformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine.

Authors:  D Samid; D M Flessate; R M Friedman
Journal:  Mol Cell Biol       Date:  1987-06       Impact factor: 4.272

2.  Cellular ras activity and phospholipid metabolism.

Authors:  C L Yu; M H Tsai; D W Stacey
Journal:  Cell       Date:  1988-01-15       Impact factor: 41.582

3.  Transformation by oncogenes encoding protein kinases induces the metastatic phenotype.

Authors:  S E Egan; J A Wright; L Jarolim; K Yanagihara; R H Bassin; A H Greenberg
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

4.  Butyrate-induced cytoarchitectural reorganization of Mallory body-containing rat hepatic tumor cells.

Authors:  M P Ryan; E Borenfreund; P J Higgins
Journal:  J Natl Cancer Inst       Date:  1987-09       Impact factor: 13.506

5.  Specificity of the interaction between phosphatidylinositol 4,5-bisphosphate and the profilin:actin complex.

Authors:  I Lassing; U Lindberg
Journal:  J Cell Biochem       Date:  1988-07       Impact factor: 4.429

6.  In vitro regulation of granulosa cell differentiation. Involvement of cytoskeletal protein expression.

Authors:  A Ben-Ze'ev; A Amsterdam
Journal:  J Biol Chem       Date:  1987-04-15       Impact factor: 5.157

7.  Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase.

Authors:  M Laiho; O Saksela; J Keski-Oja
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

8.  Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture.

Authors:  J G Rheinwald; J L Jorgensen; W C Hahn; A J Terpstra; T M O'Connell; K K Plummer
Journal:  J Cell Biol       Date:  1987-02       Impact factor: 10.539

9.  Localization of phospholipase A2 in normal and ras-transformed cells.

Authors:  D Bar-Sagi; J P Suhan; F McCormick; J R Feramisco
Journal:  J Cell Biol       Date:  1988-05       Impact factor: 10.539

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  6 in total

1.  Identification of the 52 kDa cytoskeletal-like protein of cytochalasin D-stimulated normal rat kidney (NRK/CD) cells as substrate-associated glycoprotein p52 [plasminogen-activator inhibitor type-1 (PAI-1)]. Expression of p52 (PAI-1) in NRK/CD cells is regulated at the level of mRNA abundance.

Authors:  P J Higgins; M P Ryan
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

2.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Authors:  A Saito; T Yamashita; Y Mariko; Y Nosaka; K Tsuchiya; T Ando; T Suzuki; T Tsuruo; O Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  P52PAI-1 gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphological response.

Authors:  P J Higgins; M P Ryan; D M Jelley
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

4.  Cell-shape-associated transcriptional activation of the p52(PAI-1) gene in rat kidney cells.

Authors:  P J Higgins; M P Ryan; A Ahmed
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

5.  Cell-shape-dependent modulation of p52(PAI-1) gene expression involves a secondary response pathway.

Authors:  P J Higgins; L Staiano-Coico; M P Ryan
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

6.  PAI-1 Expression Is Required for HDACi-Induced Proliferative Arrest in ras-Transformed Renal Epithelial Cells.

Authors:  Stephen P Higgins; Craig E Higgins; Paul J Higgins
Journal:  Int J Cell Biol       Date:  2011-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.